626 related articles for article (PubMed ID: 29502957)
21. Circulating tumor DNA in blood: Future genomic biomarkers for cancer detection.
Sumbal S; Javed A; Afroze B; Zulfiqar HF; Javed F; Noreen S; Ijaz B
Exp Hematol; 2018 Sep; 65():17-28. PubMed ID: 29940219
[TBL] [Abstract][Full Text] [Related]
22. The potential of ctDNA analysis in breast cancer.
Tzanikou E; Lianidou E
Crit Rev Clin Lab Sci; 2020 Jan; 57(1):54-72. PubMed ID: 31674269
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
24. Liquid biopsies.
Lianidou E; Pantel K
Genes Chromosomes Cancer; 2019 Apr; 58(4):219-232. PubMed ID: 30382599
[TBL] [Abstract][Full Text] [Related]
25. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
26. Opportunities, Challenges, and Prospects in Electrochemical Biosensing of Circulating Tumor DNA and its Specific Features.
Campuzano S; Serafín V; Gamella M; Pedrero M; Yáñez-Sedeño P; Pingarrón JM
Sensors (Basel); 2019 Aug; 19(17):. PubMed ID: 31480367
[TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
28. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
29. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
30. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
31. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
[TBL] [Abstract][Full Text] [Related]
32. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
33. Circulating Cell-Free DNA and Cancer Therapy Monitoring: Methods and Potential.
Gahan PB
Methods Mol Biol; 2019; 1909():31-46. PubMed ID: 30580421
[TBL] [Abstract][Full Text] [Related]
34. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
35. Opportunities of circulating tumor DNA in lung cancer.
Wu TH; Hsiue EH; Yang JC
Cancer Treat Rev; 2019 Aug; 78():31-41. PubMed ID: 31326635
[TBL] [Abstract][Full Text] [Related]
36. Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling.
Scherer F
Recent Results Cancer Res; 2020; 215():213-230. PubMed ID: 31605231
[TBL] [Abstract][Full Text] [Related]
37. Liquid biopsy of circulating tumor DNA and biosensor applications.
Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
[TBL] [Abstract][Full Text] [Related]
38. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
[TBL] [Abstract][Full Text] [Related]
39. A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer.
Min J; Zhou H; Jiang S; Yu H
Med Sci Monit; 2022 Feb; 28():e934106. PubMed ID: 35210388
[TBL] [Abstract][Full Text] [Related]
40. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C; Birkbak NJ; Swanton C
Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
